US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action

 
• By Sue Sutter
  
Green landscape
FDA asks whether the postmarketing study results are relevant to the current opioid landscape. (Shutterstock)

More from US Advisory Committees

More from Drug Safety